24-Dec-2024
Baxter to Present at 43rd Annual J.P. Morgan Healthcare Conference
Business Wire (Wed, 18-Dec 4:15 PM ET)
Business Wire (Wed, 11-Dec 8:00 AM ET)
Baxter to Present at 7th Annual Evercore HealthCONx Conference
Business Wire (Tue, 19-Nov 4:15 PM ET)
Baxter to Present at Jefferies London Healthcare Conference
Business Wire (Wed, 13-Nov 4:15 PM ET)
Baxter to Present at Stifel 2024 Healthcare Conference
Business Wire (Tue, 12-Nov 4:15 PM ET)
Baxter Declares Quarterly Dividend
Business Wire (Mon, 11-Nov 6:45 PM ET)
Baxter Reports Third-Quarter 2024 Results
Business Wire (Fri, 8-Nov 7:15 AM ET)
Baxter to Present at UBS Global Healthcare Conference
Business Wire (Wed, 23-Oct 4:15 PM ET)
Baxter to Host Third-Quarter 2024 Financial Results Conference Call for Investors
Business Wire (Wed, 16-Oct 4:15 PM ET)
Baxter Provides Update on North Cove, N.C., Facility and Hurricane Helene Relief Plans for Community
Business Wire (Sun, 29-Sep 4:00 PM ET)
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter has signed an agreement to sell its kidney care tools by early 2025.
Baxter Intl trades on the NYSE stock market under the symbol BAX.
As of December 24, 2024, BAX stock price declined to $29.08 with 1,490,312 million shares trading.
BAX has a beta of 0.23, meaning it tends to be less sensitive to market movements. BAX has a correlation of 0.01 to the broad based SPY ETF.
BAX has a market cap of $14.84 billion. This is considered a Large Cap stock.
Last quarter Baxter Intl reported $3 billion in Revenue and $.80 earnings per share. This fell short of revenue expectation by $-1 billion and exceeded earnings estimates by $.02.
In the last 3 years, BAX traded as high as $89.70 and as low as $28.62.
The top ETF exchange traded funds that BAX belongs to (by Net Assets): VTI, VOO, VO, SPY, IVV.
BAX has underperformed the market in the last year with a price return of -21.5% while the SPY ETF gained +28.4%. BAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.0% and -7.5%, respectively, while the SPY returned +5.6% and +0.1%, respectively.
BAX support price is $28.70 and resistance is $29.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BAX shares will trade within this expected range on the day.